Medical-device makers ResMed and Inspire slump after Lilly's Zepbound trial shows benefits for sleep apnea
By Ciara Linnane
Analysts say some patients will still need CPAP treatment
Shares of medical-device makers ResMed Inc. and Inspire Medical Systems Inc. tumbled on Monday after Eli Lilly & Co. said it has applied for regulatory approval of its weight-loss drug Zepbound to include treatment of sleep apnea.
ResMed (RMD) is the maker of a popular continuous positive airway pressure, or CPAP, machine for people with sleep apnea. Inspire Medical (INSP) makes a mask-free device for sleep apnea patients that allows them to control their treatment from the palm of their hand.
ResMed's stock was down 12.5% to put it on track for its biggest one-day percentage decline in almost a year, according to Dow Jones Market Data. The last time the stock was down that much was Aug. 4, 2023, when it fell 18.5%.
Inspire was down 15.7%, putting it on track for its worst one-day selloff since it fell 33% on May 8.
The moves came after Lilly (LLY) said Friday that Zepbound sharply reduced the restriction or blocking of airflow in patients with obesity and obstructive sleep apnea or interrupted breathing during sleep.
That was based on new late-stage trial results released by Lilly and presented at the American Diabetes Association's annual scientific conference in Orlando, Fla.
Needham analysts said they expected only a near-term headwind for ResMed and that they viewed Monday's pullback as a buying opportunity.
ResMed "had previously noted that many of the patients in the study still have clinically relevant AHIs (apnea-hypopnea index) and continued to need CPAP treatment," said analysts led by Mike Matson.
"We now expect an average 0.6%, 1.2%, and 2.2% headwind to ResMed's revenue growth over the next three years in our Bull, Base, and Bear Cases, respectively," the analysts wrote.
Lilly's stock was up 0.9% on Monday.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
06-24-24 1126ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now